Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Nektar Therapeutics
Woman and Man
Between 18 years
and 99 years
Nektar Therapeutics
Update Il y a 4 ans
Étude ATTAIN : étude de phase 3 comparant l’efficacité du NKTR-102 avec celle d’une chimiothérapie au choix du médecin chez des patients ayant un cancer du sein métastatique et des métastases cérébrales stables précédemment traités par une anthracycline, un taxane et la capécitabine. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le cancer du sein est le cancer le plus fréquent chez la femme. Il représente plus du tiers de l'ensemble des nouveaux cas de cancer chez la femme. Un cancer du sein résulte d'un dérèglement de certai...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Hormonothérapie
Essai ouvert aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Nektar Therapeutics
Update Il y a 4 ans
Étude PIVOT-02 : étude de phase 1-2 évaluant l’efficacité, la tolérance et la sécurité du NKTR-214 en association avec du nivolumab et celles du NKTR-214 en association avec du nivolumab et de l'ipilimumab chez des patients ayant des tumeurs solides malignes localement avancées ou métastatiques.
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cas de cancers. On distingue 2 t...
Country
France
organs
Tumeurs solides
,
Mélanomes cutanés
,
Rein
,
Poumon, type non à petites cellules
,
Sein
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose Disease has Failed Prior Taxane-Based Treatment
To determine the objective response rate (ORR) with NKTR-102 given on one of two schedules: once every 14 days (q14d) and once every 21 days (q21d)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
A study to compare the study drug NKTR-102 with standard treatments in breast cancer patients with stable brain metastases Un estudio para comparar el fármaco del estudio NKTR-102 con los tratamientos estándar en pacientes con cáncer de mama metastásico que tienen metástasis cerebrales estables
To compare overall survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician’s Choice (TPC) selected from the foll...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Nektar Therapeutics
Update Il y a 4 ans
Étude PIVOT10 : étude de phase 2, randomisée, en ouvert, évaluant le NKTR-214 associé au nivolumab, et une chimiothérapie, chedes patients ayant un carcinome urothélial localement avancé ou métastatique avec faible expressioPDL1, inéligible au cisplatine.
"NKTR214 1821410 PIVOT10 Etude de phase II randomisée, en ouvert, non comparative, de NKTR-214 en association avec le nivolumab et de la chimiothérapie chez les patients atteints de carcinome urothéli...
Country
France
organs
Appareil urinaire - autres
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY OF NKTR-102 IN SUBJECTS PREVIOUSLY ENROLLED IN NKTR-102 STUDIES
• To provide access to NKTR-102 to subjects who previously received NKTR-102 in a clinical trial and are without signs of disease progression since receiving NKTR-102.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Cervical Cancer
To determine the objective response rate (ORR) with NKTR-102 given on one of two schedules: once every 14 days (q14d) and once every 21 days (q21d)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Objectives: Primary Objective: To evaluate the efficacy of NKTR-118 at various dose levels, with efficacy defined as the change in the number of spontaneous bowel movements (SBMs) per week from baseli...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
An Open-Label, Multicenter, Multinational Study to Assess the Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-Ventilated Patients with Nosocomial Pneumonia
- To determine the pharmacokinetic (PK) profile of aerosolized amikacin administered via the PDDS Clinical in patients with nosocomial pneumonia caused by gram-negative organisms - To evaluate the saf...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Nektar Therapeutics
Update Il y a 4 ans
An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery system (NCPAP PDDS) in infants with respiratory distress syndrome
The primary objective is to evaluate the safety of aerosolized Curosurf delivered via nasal continuous positive airway pressure (NCPAP) in infants with RDS.
Country
None
organs
None
Specialty
None
Closed trial
More information